Clinical Trial Update: Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating rh-endostatin in combination with icotinib for advanced non-small cell lung cancer with EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)
• rh-endostatin (recombinant human endostatin)

Snippet

Sponsor: Zhejiang University | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN